H.C. Wainwright Reiterates Buy Rating on Crescent Biopharma Inc (CBIO)

October 19, 2026 8:09 AM

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $36.00 price target on Crescent Biopharma Inc (NASDAQ: CBIO).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found